# An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients

> **NCT00550407** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 215 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** lamotrigine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00550407
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2016-11-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00550407

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00550407, "An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00550407. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*